According to the U.S. Department of Health and Human Services, Black adults are nearly twice as likely as white adults to develop type 2 diabetes. This racial disparity has been rising over the last 30 years, creating a disproportionate need for certain medications in communities of color. Despite the FDA’s approval for compounding pharmacies to produce semaglutide, Novo Nordisk, a New Jersey-based pharmaceutical company that makes the drug, has targeted these providers in order to protect their profits and eliminate the competition.